Issue 3, 2014

Necrosulfonamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein

Abstract

Through high-throughput screening of 200 000 compounds and subsequent structure–activity relationship (SAR) studies we identified necrosulfonamide (NSA) as a potent small molecule inhibitor for necroptosis, induced by a combination of TNF-a, Smac mimetic, and z-VAD-fmk (T/S/Z). Applying a forward chemical genetic approach, we utilized an NSA based chemical probe to further reveal that NSA selectively targeted the Mixed Lineage Kinase Domain-like Protein (MLKL) to block the necrosome formation.

Graphical abstract: Necrosulfonamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein

Supplementary files

Article information

Article type
Concise Article
Submitted
05 Nov 2013
Accepted
19 Jan 2014
First published
12 Feb 2014

Med. Chem. Commun., 2014,5, 333-337

Necrosulfonamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein

D. Liao, L. Sun, W. Liu, S. He, X. Wang and X. Lei, Med. Chem. Commun., 2014, 5, 333 DOI: 10.1039/C3MD00278K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements